Théa Open Innovation Signs a License Agreement with Galimedix to Develop and Commercialize GAL-101 for Ophthalmic Indications
Shots:
- Galimedix will receive an up front technology access fee, success-based milestones along with royalties. Equity investment into Galimedix supports Galimedix's pipeline development
- TOI gets an exclusive right to develop & commercialize Galimedix’s GAL-101 for topical & oral treatment of dry AMD, glaucoma & other ophthalmic indications in the EU, the Americas, the Middle East & Africa. Clinical P-II/III trials with GAL-101 can now begin & 1st patient is expected to be enrolled in 2024 with initial clinical efficacy results expected about 18mos. later
- TOI will be responsible for fully funding the remaining development of GAL-101 & lead the registration and commercialization of the drug. Galimedix will lead the mid-stage clinical trials & continue to extend its pipeline incl. AD
Ref: théa | Image: théa
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
